According to the public relations of the Actover group, Dr. Shahriari, the head of the health commission of the Parliament of Iran, together with some members of the parliament and the accompanying delegation, visited the production lines of the Russian Sputnik vaccine at the Actoverco’s factory.

During this visit, which lasted about two hours, Dr. Ali Naraghi, Chairman of the Board of Directors of Actover group and some managers of the company explained the steps and production capacities of this vaccine.

This company has the ability to produce 900000 doses of Sputnik V and 3.5 million Sputnik Light per month.

According to the reports published by the Russian news agency of Sputnik, the Russian Direct Investment Fund announced that the results of the clinical trial of the Sputnik light vaccine in Azerbaijan and Russia have been very successful.

Also, according to this news agency, the injection of this type of sputnik vaccine for the ages of 18-50 years has been successful and the results of these studies have caused the increased speed of vaccination of young people in the critical situation of Russia. Sputnik Light is widely injected in 12 countries and has had beneficial effects in reducing COVID-19 incidence and mortality.

Sputnik vaccine produced in Iran has already gone through all its stages and has been sent to the Gamaleya Institute of Russia and is undergoing final tests to enter the vaccination cycle of the country.